Friday, Jun 14, 1985
South San Francisco, Calif. -- June 14, 1985 --Genentech, Inc. and Boehringer Ingelheim International GmbH (BII) jointly announced today the establishment of a research institute to be located in Vienna, Austria.
The Institute will conduct basic scientific research relating to the molecular basis of cancer. Therapeutic and diagnostic product opportunities identified by this research will be developed and commercialized by the two sponsoring companies.
The institute will use an interdisciplinary approach to its research, drawing scientists from around the world with expertise in the areas of molecular biology, protein and membrane biochemistry, cell biology and immunology. It is anticipated that the Institute will begin staffing in 1986.
Genentech and BII will contribute technical support for the Institute. BII has agreed to fund the operations of the Institute during the early years of its work. Over the long term, both Genentech and BII will provide financial support. Additional funding and assistance will be provided by the Austrian government and the City of Vienna.
Genentech is a leading biotechnology company, focusing on the development, manufacture and marketing of pharmaceuticals produced by recombinant DNA technology.
Boehringer Ingelheim is a privately held, leading pharmaceutical company based in Ingelheim, West Germany, with particular strength in the areas of cardiovascular and respiratory products. Recombinant DNA research facilities have been established in Vienna at the Ernst Boehringer Institut at Boehringer Ingelheim's subsidiary, Bender & Co. Ges mbH.
# # #